GlycoMimetics reports Phase I/II OS data for SELE-targeting AML candidate

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago next month, GlycoMimetics Inc. (NASDAQ:GLYC) reported Phase I/II data showing that twice-daily GMI-1271 plus mitoxantrone, etoposide and cytarabine (MEC) led to a median overall survival (OS) of 7.6 months at a median follow-up of 11 months in a cohort of 42 evaluable patients with relapsed or refractory acute myelogenous leukemia (AML). Mortality rates at 30 and 60 days were 0% and 7%, respectively. Additionally, the overall response rate (ORR) was 50% and the rate of complete remission (CR) or CR with incomplete blood count recovery (CRi) was 45%, matching the figure reported from 33 evaluable patients in the cohort in December (see BioCentury, Dec. 15, 2016).

GMI-1271 is an E selectin (SELE; CD62E) antagonist. Baseline expression of the SELE ligand biomarker was higher in relapsed/refractory AML patients who achieved remission, which GlycoMimetics said is the first direct clinical evidence that targeting SELE may offer a benefit in relapsed/refractory AML...